• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by MaxCyte Inc.

    5/29/25 4:30:10 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $MXCT alert in real time by email
    DEFA14A 1 tm2516505d1_defa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

    Filed by the Registrant   x

     

    Filed by a Party other than the Registrant   ¨

     

    Check the appropriate box:

     

    ¨Preliminary Proxy Statement

     

    ¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ¨Definitive Proxy Statement

     

    xDefinitive Additional Materials

     

    ¨Soliciting Material under §240.14a-12

     

    MaxCyte, Inc.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    xNo fee required

     

    ¨Fee paid previously with preliminary materials

     

    ¨Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

     

     

    YOUR VOTE MATTERS

    PLEASE VOTE TODAY

     

    May 29, 2025

     

    Dear Stockholder:

     

    The 2025 Annual Meeting of Stockholders of MaxCyte, Inc. is scheduled to take place on Wednesday, June 18, 2025 at 11:00 a.m. Eastern Time. Our recent records show that you have not yet voted your shares. Your vote is very important. Please take one moment of your time to participate in this year’s meeting by voting your proxy today.

     

    Internet and telephone voting are available for your convenience and represent the most prompt methods to record your vote. Please follow the instructions on the proxy card or voting instruction form sent to you in order to vote electronically.

     

    OVERVIEW OF PROPOSALS TO BE PRESENTED AT THE ANNUAL MEETING

     

    Proposals Board Recommendation
    1. To elect the Board’s three nominees as identified in the accompanying Proxy Statement as Class I directors: Maher Masoud, Yasir Al-Wakeel, and Rekha Hemrajani “FOR” each director nominee
    2. To approve an amendment to the MaxCyte, Inc. 2022 Equity Incentive Plan to increase the number of shares of the Company’s common stock issuable thereunder by 2,950,000 shares “FOR”
    3. To approve the cancellation of admission to trading of the Company’s common stock on AIM, a securities trading market of the London Stock Exchange plc in the United Kingdom. “FOR”
    4. To ratify the Audit Committee’s selection of CohnReznick LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025. “FOR”
    5. To approve the adjournment of the Annual Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies. “FOR”

     

    Please vote your shares today. If you need assistance voting your shares, please contact our proxy solicitor, D.F. King & Co., Inc., toll free at (866) 796-7186 or via email at [email protected].

     

    On behalf of your Board of Directors, thank you for your participation and continued support.

     

    By Order of the Board of Directors

     

     

     

    David Sandoval
    Senior Vice President, General
    Counsel and Corporate Secretary

     

     

     

    Get the next $MXCT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MXCT

    DatePrice TargetRatingAnalyst
    8/11/2025Buy → Neutral
    BTIG Research
    8/7/2025Outperform → Mkt Perform
    William Blair
    7/22/2025$6.00Overweight
    Stephens
    11/29/2023$7.00Buy
    Craig Hallum
    10/15/2021Outperform
    Cowen
    8/24/2021$36.00Outperform
    Wedbush
    8/24/2021Outperform
    William Blair
    8/24/2021$19.00Overweight
    Stephens
    More analyst ratings

    $MXCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance

    ROCKVILLE, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its second quarter ended June 30, 2025 financial results and updated its 2025 guidance. Second Quarter and Recent Highlights Core business revenue of $8.2 million in the second quarter of 2025, an increase of 8% over the second quarter of 2024.Strategic Platform License SPL Program-related revenue was $0.3 million for the second quarter of 2025, compared to $2.9 million in the second quarter of 2024, reflecting th

    8/6/25 4:05:00 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    MaxCyte Signs Platform License Agreement with Adicet Bio

    MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support development of Adicet's gamma delta T cell therapy gene edited programs ROCKVILLE, Md., Aug. 04, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced it has signed a strategic platform license (SPL) with Adicet Bio, Inc., a biotechnology company focused on the development of allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. Under the terms of the agreement, Adicet Bio will obtain non-e

    8/4/25 8:05:00 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

    ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced the signing of a Strategic Platform License Agreement (SPL) with Anocca AB, a leading, clinical stage T-cell immunotherapy company. Anocca AB will deploy MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support the scalable development and manufacturing of its deep pipeline of T-cell receptor engineered T-cell (TCR-T) cell therapies. Under the SPL, Anocca AB obtains non-exclusive research, c

    7/31/25 8:05:00 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MXCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF FINANCIAL OFFICER Swirsky Douglas J bought $64,500 worth of shares (50,000 units at $1.29), increasing direct ownership by 45% to 161,811 units (SEC Form 4)

    4 - MAXCYTE, INC. (0001287098) (Issuer)

    8/13/25 7:48:49 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    President and CEO Masoud Maher bought $102,915 worth of shares (75,000 units at $1.37), increasing direct ownership by 75% to 175,000 units (SEC Form 4)

    4 - MAXCYTE, INC. (0001287098) (Issuer)

    8/13/25 7:47:52 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Erck Stanley C bought $137,220 worth of shares (100,000 units at $1.37), increasing direct ownership by 34% to 398,328 units (SEC Form 4)

    4 - MAXCYTE, INC. (0001287098) (Issuer)

    8/13/25 7:47:13 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MXCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    MaxCyte downgraded by BTIG Research

    BTIG Research downgraded MaxCyte from Buy to Neutral

    8/11/25 9:48:40 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    MaxCyte downgraded by William Blair

    William Blair downgraded MaxCyte from Outperform to Mkt Perform

    8/7/25 7:35:46 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Stephens initiated coverage on MaxCyte with a new price target

    Stephens initiated coverage of MaxCyte with a rating of Overweight and set a new price target of $6.00

    7/22/25 7:53:47 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MXCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF FINANCIAL OFFICER Swirsky Douglas J bought $64,500 worth of shares (50,000 units at $1.29), increasing direct ownership by 45% to 161,811 units (SEC Form 4)

    4 - MAXCYTE, INC. (0001287098) (Issuer)

    8/13/25 7:48:49 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    President and CEO Masoud Maher bought $102,915 worth of shares (75,000 units at $1.37), increasing direct ownership by 75% to 175,000 units (SEC Form 4)

    4 - MAXCYTE, INC. (0001287098) (Issuer)

    8/13/25 7:47:52 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Erck Stanley C bought $137,220 worth of shares (100,000 units at $1.37), increasing direct ownership by 34% to 398,328 units (SEC Form 4)

    4 - MAXCYTE, INC. (0001287098) (Issuer)

    8/13/25 7:47:13 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MXCT
    SEC Filings

    View All

    MaxCyte Inc. filed SEC Form 8-K: Leadership Update

    8-K - MAXCYTE, INC. (0001287098) (Filer)

    8/11/25 4:30:15 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-Q filed by MaxCyte Inc.

    10-Q - MAXCYTE, INC. (0001287098) (Filer)

    8/6/25 4:46:55 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    MaxCyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MAXCYTE, INC. (0001287098) (Filer)

    8/6/25 4:13:16 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MXCT
    Leadership Updates

    Live Leadership Updates

    View All

    MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

    ROCKVILLE, Md., Dec. 08, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the completion of an internal operational review, initiated earlier this year following the appointment of Maher Masoud as President and Chief Executive Officer. This "bottom-up" review focused on optimizing new product development, manufacturing, commercial execution, and capital allocation to enhance efficiency and align resources with strategic priorities. As part of an effort to streamline operations,

    12/9/24 2:00:00 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    MaxCyte Appoints Cynthia Collins to its Board of Directors

    ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members. "I am pleased to welcome Cynthia to MaxCyte's Board of Directors," said Mahe

    10/15/24 8:05:00 AM ET
    $CERT
    $MXCT
    $PSTX
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

    ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer, effective as of September 11, 2024. In his new role, Mr. Soleymannezhad will lead MaxCyte's commercial operations to increase adoption of the ExPERT Platform, provide best-in-class scientific, technical and regulatory support to customers, and expand the Company's market impact in Cell and

    10/10/24 8:05:00 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MXCT
    Financials

    Live finance-specific insights

    View All

    MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance

    ROCKVILLE, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its second quarter ended June 30, 2025 financial results and updated its 2025 guidance. Second Quarter and Recent Highlights Core business revenue of $8.2 million in the second quarter of 2025, an increase of 8% over the second quarter of 2024.Strategic Platform License SPL Program-related revenue was $0.3 million for the second quarter of 2025, compared to $2.9 million in the second quarter of 2024, reflecting th

    8/6/25 4:05:00 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

    ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced the signing of a Strategic Platform License Agreement (SPL) with Anocca AB, a leading, clinical stage T-cell immunotherapy company. Anocca AB will deploy MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support the scalable development and manufacturing of its deep pipeline of T-cell receptor engineered T-cell (TCR-T) cell therapies. Under the SPL, Anocca AB obtains non-exclusive research, c

    7/31/25 8:05:00 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025

    ROCKVILLE, Md., July 09, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the second quarter 2025 after the U.S. market close on Wednesday, August 6th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call DetailsInvestors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live an

    7/9/25 8:05:00 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MXCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by MaxCyte Inc.

    SC 13G/A - MAXCYTE, INC. (0001287098) (Subject)

    11/13/24 7:14:35 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13G/A filed by MaxCyte Inc.

    SC 13G/A - MAXCYTE, INC. (0001287098) (Subject)

    10/31/24 4:23:48 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G filed by MaxCyte Inc.

    SC 13G - MAXCYTE, INC. (0001287098) (Subject)

    3/25/24 4:36:08 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care